Metabolic differences between Asian and Caucasian patients on clozapine treatment

Human Psychopharmacology

Volumn 22, Issue 4, 2007, Pages 217-222

  Subramaniam, Mythily ^a   Ng, Chee ^b   Chong, Siow Ann ^a   Mahendran, Rathi ^a   Lambert, Tim ^b   Pek, Elaine ^a   Chan, Yiong Huak ^c  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Body mass index; Clozapine; Ethnicity; Hypertension; Schizophrenia; Treatment resistance

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CLOZAPINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE; BODY MASS; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ETHNIC DIFFERENCE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; LIVER FUNCTION TEST; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; SCHIZOPHRENIA; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL; CLOZAPINE; DIET; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; TRIGLYCERIDES;

EID: 34250634849     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.842     Document Type: Article

References (29)

1. American Diabetes Association. 2004. Diagnosis and classification of diabetes mellitus. Diabetes Care 27: S5-S10.
2. American Psychiatric Association. 2004. Practice guideline for the treatment of patients with schizophrenia, 2nd edition. Am J Psychiatry 161(2 suppl): 1S-56S.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition. American Psychiatric Association: Washington, DC, 1994.
4. Baymiller SP, Ball P, McMahon RP, Buchanan RW. 2003. Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. Schizophr Res 59: 49-57.
5. Bautista LE, Orostegui M, Vera LM, Prada GE, Orozco LC, Herran OF. 2006. Prevalence and impact of cardiovascular risk factors in Bucaramanga, Colombia: results from the Countrywide Integrated Noncommunicable Disease Intervention Programme (CINDI/CARMEN) baseline survey. Eur J Cardiovasc Prev Rehabil 13: 769-775.
6. Casey DE. 1989. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology (Berl.) 99: S47-S53.
7. Chong SA, Tan CH, Khoo YM, et al. 1997. Clinical evaluation and plasma clozapine concentrations in Chinese patients with schizophrenia. Ther Drug Monit 19: 219-223.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 2001. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285: 2486-2497.
9. Fitton A, Heel RC. 1990. Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 40: 722-747.
10. Gaertner I, Altendorf K, Batra A, Gaertner HJ. 2000. Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses. J Clin Psychopharmacol 21: 215-222.
11. Gaulin BD, Markowitz JS, Caley CF, Nesbitt LA, Dufresne RL. 1999. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 156: 1270-1272.
12. Grant DM, Tang BK, Kalow W. 1983. Variability in caffeine metabolism. Clin Pharmacol Ther 33: 591-602.
13. Jerling M, Lindstrom L, Bondesson U, Bertilsson L. 1994. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 16: 368-374.
14. Kalow W, Tang BK. 1991. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 50: 508-519.
15. Kane J, Honigfeld G, Singer J, Meltzer H. 1988. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789-796.
16. Kane JM. 1996. Treatment-resistant schizophrenic patients. J Clin Psychiatry 57: 35-40.
17. Landi MT, Sinha R, Lang NP, Kadlubar FF. 1999. Human cytochrome P4501 A2. IARC Sci Publ 148: 173-195.
18. Lehman AF, Lieberman JA, Dixon LB, et al. 2004. American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161: 1-56.
19. Lindenmayer JP, Czobor P, Volavka J, et al. 2003. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 160: 290-296.
20. Matsuda KT, Cho MC, Lin KM, Smith MW, Young AS, Adams JA. 1996. Clozapine dosage, serum levels, efficacy, and side-effect profiles: a comparison of Korean-American and Caucasian patients. Psychopharmacol Bull 32: 253-257.
21. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T. 1999. Genetic polymorphism in the 5′-falnking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in Humans. J Biochem 125: 803-808.
22. Ng CH, Chong SA, Lambert T, et al. 2005. An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. Int Clin Psychopharmacol 20: 163-168.
23. Popli AP, Konicki PE, Jurjus GJ, Fuller MA, Jaskiw GE. 1997. Clozapine and associated diabetes mellitus. J Clin Psychiatry 58: 108-111.
24. Reeder BA, Angel A, Ledoux M, Rabkin SW, Young TK, Sweet LE. 1992. Obesity and its relation to cardiovascular disease risk factors in Canadian adults. Canadian Heart Health Surveys Research Group. CMAJ 146: 2009-2019.
25. Sachse C, Brockmoller J, Bauer S, Roots I. 1999. Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47: 445-449.
26. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drags, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Other 270: 414-423.
27. Singh V, Deedwania P. 2006. Dyslipidemia in special populations: Asian Indians, African Americans, and Hispanics. Curr Atheroscler Rep 8: 32-40.
28. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. 2002. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 63: 856-865.
29. World Heath Organisation. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series, No 854, 1995.